Literature DB >> 9657431

The diagnostic value of thrombopoietin level measurements in thrombocytopenia.

L Porcelijn1, C C Folman, B Bossers, E Huiskes, M A Overbeeke, C E v d Schoot, M de Haas, A E von dem Borne.   

Abstract

It has been reported that blood trombopoietin (TPO) levels can discriminate between thrombocytopenia due to increased platelet destruction and decreased platelet production. With our TPO ELISA and a glycocalicin ELISA we analysed a large group of patients in detail and could confirm and amplify the above notion in detail. TPO levels were determined in plasma from 178 clinically and serologically well-defined thrombocytopenic patients: 72 patients with idiopathic autoimmune thrombocytopenia (AITP), 29 patients with secondary AITP, 5 patients with amegakaryocytic thrombocytopenia and 72 patients who suffered from various diseases (46 in whom megakaryocyte deficiency was not and 26 in whom it was expected). In addition, we measured the level of glycocalicin as a marker of total body mass of platelets. In all patients with primary AITP and secondary AITP, TPO levels were within the normal range or in some (n = 7) cases only slightly increased. The level of glycocalicin was not significantly different from that of the controls (n = 95). The patients with amegakaryocytic thrombocytopenia had strongly elevated TPO levels and significantly decreased glycocalicin levels. Similarly, among the 72 thrombocytopenic patients with various disorders, elevated TPO levels were only found in patients in whom platelet production was depressed. The mean level of glycocalicin in these patients was decreased compared to that in controls and patients with AITP, but was not as low as in patients with amegakaryocytic thrombocytopenia. In conclusion, all patients with depressed platelet production had elevated levels of circulating TPO, whereas the TPO levels in patients with an immune-mediated thrombocytopenia were mostly within the normal range. Therefore, measurement of plasma TPO levels provides valuable diagnostic information for the analysis of thrombocytopenia in general. Moreover, treatment with TPO may be an option in AITP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657431

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

Review 1.  [Adult autoimmune thrombocytopenia: diagnosis and treatment].

Authors:  Klaus Lechner; Ansgar Weltermann; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

2.  Anti-glycoprotein Ibα autoantibodies do not impair circulating thrombopoietin levels in immune thrombocytopenia patients.

Authors:  Leendert Porcelijn; David E Schmidt; C Ellen van der Schoot; Gestur Vidarsson; Masja de Haas; Rick Kapur
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

Review 3.  From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.

Authors:  Harinder Gill; Raymond S M Wong; Yok-Lam Kwong
Journal:  Ther Adv Hematol       Date:  2017-02-01

Review 4.  Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Authors:  Roberto Stasi; Maria L Evangelista; Sergio Amadori
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

Review 6.  Pathophysiology and management of primary immune thrombocytopenia.

Authors:  Hirokazu Kashiwagi; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

7.  Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.

Authors:  David E Schmidt; Katja M J Heitink-Polle; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Marrie C A Bruin; Masja de Haas
Journal:  J Thromb Haemost       Date:  2020-04-12       Impact factor: 5.824

8.  Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma.

Authors:  Yukihiro Nishikawa; Shiyo Nishida; Keiko Kuroda; Hirokazu Kashiwagi; Yoshiaki Tomiyama; Masataka Kuwana
Journal:  Diagnostics (Basel)       Date:  2022-01-26

9.  Primary immune thrombocytopenia: a 'diagnosis of exclusion'?

Authors:  Nathan Visweshwar; Irmel Ayala; Michael Jaglal; Robert Killeen; Lubomir Sokol; Damian A Laber; Arumugam Manoharan
Journal:  Blood Coagul Fibrinolysis       Date:  2022-07-29       Impact factor: 1.061

10.  A cross-sectional study on thrombopoietin levels in immune thrombocytopenia and its correlation with platelet count, megakaryocytes, and treatment response.

Authors:  Gurleen Oberoi; Mili Jain; Shankar Madhav Natu; Rashmi Kushwaha; Anil Kumar Tripathi; Ashutosh Kumar
Journal:  Asian J Transfus Sci       Date:  2022-05-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.